Cobimetinib
- Generic Name
- Cobimetinib
- Brand Names
- Cotellic
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21F3IN3O2
- CAS Number
- 934660-93-2
- Unique Ingredient Identifier
- ER29L26N1X
- Background
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metasta...
- Indication
Cobimetinib is indicated in combination with vemurafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. As a single agent, cobimetinib is also indicated for the treatment of adult patients with histiocytic neoplasms.
- Associated Conditions
- Histiocytic Neoplasm, Metastatic Melanoma, Unresectable Melanoma
- Associated Therapies
- -
Study of Cobimetinib in Participants With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT00467779
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.